BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Homaira N, Rawlinson W, Snelling TL, Jaffe A. Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective. Int J Pediatr 2014;2014:571609. [PMID: 25548575 DOI: 10.1155/2014/571609] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Flynn JA, Durr E, Swoyer R, Cejas PJ, Horton MS, Galli JD, Cosmi SA, Espeseth AS, Bett AJ, Zhang L. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein. PLoS One 2016;11:e0164789. [PMID: 27764150 DOI: 10.1371/journal.pone.0164789] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
2 Yeo KT, Yung CF, Khoo PC, Saffari SE, Sng JSP, How MS, Quek BH. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation. J Infect Dis 2021;224:279-87. [PMID: 33274362 DOI: 10.1093/infdis/jiaa749] [Reference Citation Analysis]
3 Sirimi N, Miligkos M, Koutouzi F, Petridou E, Siahanidou T, Michos A. Respiratory syncytial virus activity and climate parameters during a 12-year period. J Med Virol 2016;88:931-7. [PMID: 26575521 DOI: 10.1002/jmv.24430] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
4 Fearns R, Deval J. New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase. Antiviral Res 2016;134:63-76. [PMID: 27575793 DOI: 10.1016/j.antiviral.2016.08.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
5 Edupuganti S, Mgodi N, Karuna ST, Andrew P, Rudnicki E, Kochar N, deCamp A, De La Grecca R, Anderson M, Karg C, Tindale I, Greene E, Broder GB, Lucas J, Hural J, Gallardo-Cartagena JA, Gonzales P, Frank I, Sobieszczyk M, Gomez Lorenzo MM, Burns D, Anderson PL, Miner MD, Ledgerwood J, Mascola JR, Gilbert PB, Cohen MS, Corey L; HVTN 704/HPTN 085 study group. Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. J Acquir Immune Defic Syndr 2021;87:671-9. [PMID: 33587505 DOI: 10.1097/QAI.0000000000002639] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 German P, Xin Y, Chien JW, Weng W, Mackman R, Lewis SA, Meng A, Ling J, Mathias A. Phase 1 First-in-Human, Single- and Multiple-Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of Respiratory Syncytial Virus Infection. J Clin Pharmacol 2018;58:1025-34. [PMID: 29663420 DOI: 10.1002/jcph.1112] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
7 Leemans A, Boeren M, Van der Gucht W, Martinet W, Caljon G, Maes L, Cos P, Delputte P. Characterization of the role of N-glycosylation sites in the respiratory syncytial virus fusion protein in virus replication, syncytium formation and antigenicity. Virus Res 2019;266:58-68. [PMID: 31004621 DOI: 10.1016/j.virusres.2019.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 Bawage SS, Tiwari PM, Pillai S, Dennis VA, Singh SR. Antibiotic Minocycline Prevents Respiratory Syncytial Virus Infection. Viruses 2019;11:E739. [PMID: 31405261 DOI: 10.3390/v11080739] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Schobel SA, Stucker KM, Moore ML, Anderson LJ, Larkin EK, Shankar J, Bera J, Puri V, Shilts MH, Rosas-Salazar C, Halpin RA, Fedorova N, Shrivastava S, Stockwell TB, Peebles RS, Hartert TV, Das SR. Respiratory Syncytial Virus whole-genome sequencing identifies convergent evolution of sequence duplication in the C-terminus of the G gene. Sci Rep 2016;6:26311. [PMID: 27212633 DOI: 10.1038/srep26311] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
10 Robinson JL, Le Saux N; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health 2015;20:321-33. [PMID: 26435673 DOI: 10.1093/pch/20.6.321] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
11 Xiao X, Tang A, Cox KS, Wen Z, Callahan C, Sullivan NL, Nahas DD, Cosmi S, Galli JD, Minnier M, Verma D, Babaoglu K, Su H, Bett AJ, Vora KA, Chen Z, Zhang L. Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes. MAbs 2019;11:1415-27. [PMID: 31402751 DOI: 10.1080/19420862.2019.1654304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Divarathne MVM, Ahamed RR, Noordeen F. The Impact of RSV-Associated Respiratory Disease on Children in Asia. J Pediatr Infect Dis 2019;14:79-88. [PMID: 32300274 DOI: 10.1055/s-0038-1637752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
13 Goodwin E, Gilman MSA, Wrapp D, Chen M, Ngwuta JO, Moin SM, Bai P, Sivasubramanian A, Connor RI, Wright PF, Graham BS, McLellan JS, Walker LM. Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation. Immunity 2018;48:339-349.e5. [PMID: 29396163 DOI: 10.1016/j.immuni.2018.01.005] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 18.0] [Reference Citation Analysis]
14 Yoshida I, Arikawa K, Honma Y, Inatani S, Yoshinaga M, Sugiyama H. Pharmacological Characterization of TP0591816, a Novel Macrocyclic Respiratory Syncytial Virus Fusion Inhibitor with Antiviral Activity against F Protein Mutants. Antimicrob Agents Chemother 2020;65:e01407-20. [PMID: 33046486 DOI: 10.1128/AAC.01407-20] [Reference Citation Analysis]
15 Leemans A, De Schryver M, Van der Gucht W, Heykers A, Pintelon I, Hotard AL, Moore ML, Melero JA, McLellan JS, Graham BS, Broadbent L, Power UF, Caljon G, Cos P, Maes L, Delputte P. Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein. J Virol 2017;91:e00184-17. [PMID: 28468888 DOI: 10.1128/JVI.00184-17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 Resch B, Bramreiter VS, Kurath-Koller S, Freidl T, Urlesberger B. Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis. Eur J Clin Microbiol Infect Dis 2017;36:1057-62. [PMID: 28078558 DOI: 10.1007/s10096-016-2891-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wang DY, Li A, Paes B, Mitchell I, Lanctôt KL; CARESS Investigators. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015). Eur J Pediatr 2017;176:413-22. [PMID: 28105526 DOI: 10.1007/s00431-017-2849-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
18 Lambkin-Williams R, Noulin N, Mann A, Catchpole A, Gilbert AS. The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics. Respir Res 2018;19:123. [PMID: 29929556 DOI: 10.1186/s12931-018-0784-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
19 Stittelaar KJ, de Waal L, van Amerongen G, Veldhuis Kroeze EJ, Fraaij PL, van Baalen CA, van Kampen JJ, van der Vries E, Osterhaus AD, de Swart RL. Ferrets as a Novel Animal Model for Studying Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Hosts. Viruses 2016;8:E168. [PMID: 27314379 DOI: 10.3390/v8060168] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
20 Zhang L, Durr E, Galli JD, Cosmi S, Cejas PJ, Luo B, Touch S, Parmet P, Fridman A, Espeseth AS, Bett AJ. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability. Vaccine 2018;36:8119-30. [PMID: 30340881 DOI: 10.1016/j.vaccine.2018.10.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
21 Metz J, Eber E, Resch B. Respiratory Syncytial Virus Infection-associated Hospitalization Rates in Infants and Children With Cystic Fibrosis. Pediatr Infect Dis J 2017;36:545-8. [PMID: 28005688 DOI: 10.1097/INF.0000000000001501] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
22 Nye S, Whitley RJ, Kong M. Viral Infection in the Development and Progression of Pediatric Acute Respiratory Distress Syndrome. Front Pediatr 2016;4:128. [PMID: 27933286 DOI: 10.3389/fped.2016.00128] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
23 Tang A, Chen Z, Cox KS, Su HP, Callahan C, Fridman A, Zhang L, Patel SB, Cejas PJ, Swoyer R, Touch S, Citron MP, Govindarajan D, Luo B, Eddins M, Reid JC, Soisson SM, Galli J, Wang D, Wen Z, Heidecker GJ, Casimiro DR, DiStefano DJ, Vora KA. A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun 2019;10:4153. [PMID: 31515478 DOI: 10.1038/s41467-019-12137-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
24 Maeurer M, Rao M, Zumla A. Host-directed therapies for antimicrobial resistant respiratory tract infections: . Current Opinion in Pulmonary Medicine 2016;22:203-11. [DOI: 10.1097/mcp.0000000000000271] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
25 Stewart-Jones GB, Thomas PV, Chen M, Druz A, Joyce MG, Kong WP, Sastry M, Soto C, Yang Y, Zhang B, Chen L, Chuang GY, Georgiev IS, McLellan JS, Srivatsan S, Zhou T, Baxa U, Mascola JR, Graham BS, Kwong PD. A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. PLoS One 2015;10:e0128779. [PMID: 26098893 DOI: 10.1371/journal.pone.0128779] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
26 Jones HG, Ritschel T, Pascual G, Brakenhoff JPJ, Keogh E, Furmanova-Hollenstein P, Lanckacker E, Wadia JS, Gilman MSA, Williamson RA, Roymans D, van 't Wout AB, Langedijk JP, McLellan JS. Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies. PLoS Pathog 2018;14:e1006935. [PMID: 29509814 DOI: 10.1371/journal.ppat.1006935] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
27 Leemans A, Boeren M, Van der Gucht W, Pintelon I, Roose K, Schepens B, Saelens X, Bailey D, Martinet W, Caljon G, Maes L, Cos P, Delputte P. Removal of the N-Glycosylation Sequon at Position N116 Located in p27 of the Respiratory Syncytial Virus Fusion Protein Elicits Enhanced Antibody Responses after DNA Immunization. Viruses 2018;10:E426. [PMID: 30110893 DOI: 10.3390/v10080426] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
28 Smith TRF, Schultheis K, Morrow MP, Kraynyak KA, McCoy JR, Yim KC, Muthumani K, Humeau L, Weiner DB, Sardesai NY, Broderick KE. Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus. Vaccine 2017;35:2840-7. [PMID: 28413132 DOI: 10.1016/j.vaccine.2017.04.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
29 Sutto-Ortiz P, Tcherniuk S, Ysebaert N, Abeywickrema P, Noël M, Decombe A, Debart F, Vasseur JJ, Canard B, Roymans D, Rigaux P, Eléouët JF, Decroly E. The methyltransferase domain of the Respiratory Syncytial Virus L protein catalyzes cap N7 and 2'-O-methylation. PLoS Pathog 2021;17:e1009562. [PMID: 33956914 DOI: 10.1371/journal.ppat.1009562] [Reference Citation Analysis]
30 Abraha HY, Lanctôt KL, Paes B. Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. Expert Rev Respir Med 2015;9:779-99. [PMID: 26457970 DOI: 10.1586/17476348.2015.1098536] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
31 Hong T, Bolisetty S, Bajuk B, Abdel-latif M, Oei J, Jaffe A, Lui K. A population study of respiratory rehospitalisation in very preterm infants in the first 3 years of life: Respiratory readmissions of preterms. Journal of Paediatrics and Child Health 2016;52:715-21. [DOI: 10.1111/jpc.13205] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
32 Jones HG, Battles MB, Lin CC, Bianchi S, Corti D, McLellan JS. Alternative conformations of a major antigenic site on RSV F. PLoS Pathog 2019;15:e1007944. [PMID: 31306469 DOI: 10.1371/journal.ppat.1007944] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
33 Gilman MSA, Liu C, Fung A, Behera I, Jordan P, Rigaux P, Ysebaert N, Tcherniuk S, Sourimant J, Eléouët JF, Sutto-Ortiz P, Decroly E, Roymans D, Jin Z, McLellan JS. Structure of the Respiratory Syncytial Virus Polymerase Complex. Cell 2019;179:193-204.e14. [PMID: 31495574 DOI: 10.1016/j.cell.2019.08.014] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 17.7] [Reference Citation Analysis]
34 Anderson AJ, Snelling TL, Moore HC, Blyth CC. Advances in Vaccines to Prevent Viral Respiratory Illnesses in Children. Paediatr Drugs 2017;19:523-31. [PMID: 28808938 DOI: 10.1007/s40272-017-0257-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
35 Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol 2019;17:233-45. [PMID: 30723301 DOI: 10.1038/s41579-019-0149-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 25.0] [Reference Citation Analysis]
36 Chen Z, Zhang L, Tang A, Callahan C, Pristatsky P, Swoyer R, Cejas P, Nahas D, Galli J, Cosmi S, DiStefano D, Hoang VM, Bett A, Casimiro D, Vora KA. Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein. PLoS One 2016;11:e0156798. [PMID: 27258388 DOI: 10.1371/journal.pone.0156798] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
37 Kwong PD. What Are the Most Powerful Immunogen Design Vaccine Strategies? A Structural Biologist's Perspective. Cold Spring Harb Perspect Biol 2017;9:a029470. [PMID: 28159876 DOI: 10.1101/cshperspect.a029470] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
38 Maas BM, Lommerse J, Plock N, Railkar RA, Cheung SYA, Caro L, Chen J, Liu W, Zhang Y, Huang Q, Gao W, Qin L, Meng J, Witjes H, Schindler E, Guiastrennec B, Bellanti F, Spellman DS, Roadcap B, Kalinova M, Fok-Seang J, Catchpole AP, Espeseth AS, Stoch SA, Lai E, Vora KA, Aliprantis AO, Sachs JR. Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis. EBioMedicine 2021;73:103651. [PMID: 34775220 DOI: 10.1016/j.ebiom.2021.103651] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Newby B, Sorokan T. Respiratory Syncytial Virus Infection Rates with Limited Use of Palivizumab for Infants Born at 29 to 31+6/7 Weeks Gestational Age. Can J Hosp Pharm 2017;70:13-8. [PMID: 28348428 DOI: 10.4212/cjhp.v70i1.1623] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
40 Sánchez-Luna M, Medrano C, Lirio J; RISK-21 Study Group. Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study. Influenza Other Respir Viruses 2017;11:157-64. [PMID: 27611835 DOI: 10.1111/irv.12431] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
41 González AE, Lay MK, Jara EL, Espinoza JA, Gómez RS, Soto J, Rivera CA, Abarca K, Bueno SM, Riedel CA, Kalergis AM. Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection. Virulence 2017;8:685-704. [PMID: 27911218 DOI: 10.1080/21505594.2016.1265725] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
42 Broberg EK, Waris M, Johansen K, Snacken R, Penttinen P; European Influenza Surveillance Network. Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016. Euro Surveill 2018;23. [PMID: 29409569 DOI: 10.2807/1560-7917.ES.2018.23.5.17-00284] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 13.3] [Reference Citation Analysis]
43 Reis J, Yamana T, Kandula S, Shaman J. Superensemble forecast of respiratory syncytial virus outbreaks at national, regional, and state levels in the United States. Epidemics 2019;26:1-8. [PMID: 30025885 DOI: 10.1016/j.epidem.2018.07.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
44 Huang Y, Zhang L, Ledgerwood J, Grunenberg N, Bailer R, Isaacs A, Seaton K, Mayer KH, Capparelli E, Corey L, Gilbert PB. Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. MAbs 2017;9:792-800. [PMID: 28368743 DOI: 10.1080/19420862.2017.1311435] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
45 Silva THD, Pinho JRR, Silva Junior TJD, Carmona F. Epidemiology of viral respiratory infections in children undergoing heart surgery. Prog Pediatr Cardiol 2019;52:22-5. [PMID: 32288462 DOI: 10.1016/j.ppedcard.2018.09.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Liu B, Park S, Thompson CD, Li X, Lee JC. Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo. Virulence 2017;8:859-74. [PMID: 27936346 DOI: 10.1080/21505594.2016.1270494] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
47 Gilca R, Billard MN, Zafack J, Papenburg J, Boucher FD, Charest H, Rochette M, De Serres G. Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada. Prev Med Rep 2020;20:101180. [PMID: 32953425 DOI: 10.1016/j.pmedr.2020.101180] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
48 Zhou L, Xu J, Dai C, Fan Y, Yuan B. Label-free quantitative proteomics reveals fibrinopeptide B and heparin cofactor II as potential serum biomarkers in respiratory syncytial virus-infected mice treated with Qingfei oral liquid formula. Chinese Journal of Natural Medicines 2018;16:241-51. [DOI: 10.1016/s1875-5364(18)30054-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Xu JJ, Liu Z, Tang W, Wang GC, Chung HY, Liu QY, Zhuang L, Li MM, Li YL. Tangeretin from Citrus reticulate Inhibits Respiratory Syncytial Virus Replication and Associated Inflammation in Vivo. J Agric Food Chem 2015;63:9520-7. [PMID: 26468759 DOI: 10.1021/acs.jafc.5b03482] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
50 Gilman MS, Moin SM, Mas V, Chen M, Patel NK, Kramer K, Zhu Q, Kabeche SC, Kumar A, Palomo C, Beaumont T, Baxa U, Ulbrandt ND, Melero JA, Graham BS, McLellan JS. Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. PLoS Pathog 2015;11:e1005035. [PMID: 26161532 DOI: 10.1371/journal.ppat.1005035] [Cited by in Crossref: 82] [Cited by in F6Publishing: 85] [Article Influence: 11.7] [Reference Citation Analysis]
51 Prat C, Lacoma A. Bacteria in the respiratory tract-how to treat? Or do not treat? Int J Infect Dis 2016;51:113-22. [PMID: 27776777 DOI: 10.1016/j.ijid.2016.09.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
52 Kong MY, Whitley RJ, Peng N, Oster R, Schoeb TR, Sullender W, Ambalavanan N, Clancy JP, Gaggar A, Blalock JE. Matrix Metalloproteinase-9 Mediates RSV Infection in Vitro and in Vivo. Viruses 2015;7:4230-53. [PMID: 26264019 DOI: 10.3390/v7082817] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
53 Mitchell I, Li A, Bjornson CL, Lanctot KL, Paes BA; CARESS investigators. Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada. Am J Perinatol 2021. [PMID: 33657636 DOI: 10.1055/s-0041-1725146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]